Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications (Articolo in rivista)

Type

• Articolo in rivista (Classe)
• Prodotto della ricerca (Classe)

Label

• Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications (Articolo in rivista) (literal)

Anno

• 2008-01-01T00:00:00+01:00 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

• 10.1016/j.atherosclerosis.2007.07.025 (literal)

Alternative label

• Basta G. (2008)
  Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications
  in Atherosclerosis (Amst.)
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Basta G. (literal)

Pagina inizio

• 9 (literal)

Pagina fine

• 12 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url

• http://dx.doi.org/10.1016/j.atherosclerosis.2007.07.025 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 196 (literal)

Rivista

• Atherosclerosis (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#note

• In: Atherosclerosis, vol. 196 (1) pp. 9 - 12. Elsevier, 2008. (literal)

Note

• PubMe (literal)
• ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• CNR, Institute of Clinical Physiology, Pisa, Italy (literal)

Titolo

• Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications (literal)

Abstract

• The receptor for advanced glycation endproducts (RAGE) is a member of the immunoglobulin superfamily of cell-surface molecules with a diverse repertoire of ligands. In the atherosclerotic milieu, three classes of RAGE ligands, i.e., products of non-enzymatic glycoxidation, S100 proteins and amphoterin, appear to drive receptor-mediated cellular activation and potentially, acceleration of vascular disease. The interaction of RAGE-ligands effectively modulates several steps of atherogenesis, triggering an inflammatory-proliferative process and furthermore, critically contributing to propagation of vascular perturbation, mainly in diabetes. RAGE has a circulating truncated variant isoform, soluble RAGE (sRAGE), corresponding to its extracellular domain only. By competing with cell-surface RAGE for ligand binding, sRAGE may contribute to the removal/neutralization of circulating ligands thus functioning as a decoy. The critical role of RAGE in the chronic vascular inflammation processes highlights this receptor-ligand axis as a possible and attractive candidate for therapeutic intervention to limit vascular damage and its associated clinical disorders. (literal)

Prodotto di

• Istituto di fisiologia clinica (IFC) (Istituto)
• MEDICINA TRASLAZIONALE (ME.P05.016.001) (Modulo)

Autore CNR

• GIUSEPPINA BASTA (Persona)

Insieme di parole chiave

• Parole chiave di "Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications" (Insieme di parole chiave)

Incoming links:

Prodotto

• Istituto di fisiologia clinica (IFC) (Istituto)
• MEDICINA TRASLAZIONALE (ME.P05.016.001) (Modulo)

Autore CNR di

• GIUSEPPINA BASTA (Persona)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• Atherosclerosis (Rivista)

Insieme di parole chiave di

• Parole chiave di "Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications" (Insieme di parole chiave)